Systematic Review and Meta-analysis of the Prevalence of Chronic Fatigue Syndrome/myalgic Encephalomyelitis (CFS/ME)
Overview
General Medicine
Affiliations
Background: Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) has been emerging as a significant health issue worldwide. This study aimed to systemically assess the prevalence of CFS/ME in various aspects of analyses for precise assessment.
Methods: We systematically searched prevalence of CFS/ME from public databases from 1980 to December 2018. Data were extracted according to 7 categories for analysis: study participants, gender and age of the participants, case definition, diagnostic method, publication year, and country of the study conducted. Prevalence data were collected and counted individually for studies adopted various case definitions. We analyzed and estimated prevalence rates in various angles: average prevalence, pooled prevalence and meta-analysis of all studies.
Results: A total of 1291 articles were initially identified, and 45 articles (46 studies, 56 prevalence data) were selected for this study. Total 1085,976 participants were enrolled from community-based survey (540,901) and primary care sites (545,075). The total average prevalence was 1.40 ± 1.57%, pooled prevalence 0.39%, and meta-analysis 0.68% [95% CI 0.48-0.97]. The prevalence rates were varied by enrolled participants (gender, study participants, and population group), case definitions and diagnostic methods. For example, in the meta-analysis; women (1.36% [95% CI 0.48-0.97]) vs. men (0.86% [95% CI 0.48-0.97]), community-based samples (0.76% [95% CI 0.53-1.10]) vs. primary care sites (0.63% [95% CI 0.37-1.10]), adults ≥ 18 years (0.65% [95% CI 0.43-0.99]) vs. children and adolescents < 18 years (0.55% [95% CI 0.22-1.35]), CDC-1994 (0.89% [95% CI 0.60-1.33]) vs. Holmes (0.17% [95% CI 0.06-0.49]), and interviews (1.14% [95% CI 0.76-1.72]) vs. physician diagnosis (0.09% [95% CI 0.05-0.13]), respectively.
Conclusions: This study comprehensively estimated the prevalence of CFS/ME; 0.89% according to the most commonly used case definition CDC-1994, with women approximately 1.5 to 2 folds higher than men in all categories. However, we observed the prevalence rates are widely varied particularly by case definitions and diagnostic methods. An objective diagnostic tool is urgently required for rigorous assessment of the prevalence of CFS/ME.
Vardaman M, Gilmour S J Transl Med. 2025; 23(1):331.
PMID: 40087760 DOI: 10.1186/s12967-025-06281-0.
Weigel B, Inderyas M, Eaton-Fitch N, Thapaliya K, Marshall-Gradisnik S J Transl Med. 2025; 23(1):318.
PMID: 40075382 PMC: 11905571. DOI: 10.1186/s12967-025-06131-z.
mTORC1 syndrome (TorS): unifying paradigm for PASC, ME/CFS and PAIS.
Bar-Tana J J Transl Med. 2025; 23(1):297.
PMID: 40059164 PMC: 11892318. DOI: 10.1186/s12967-025-06220-z.
Hung L, Wu C, Chang C, Li P, Hicks K, Dibble J Front Hum Neurosci. 2025; 19:1509346.
PMID: 39996021 PMC: 11847890. DOI: 10.3389/fnhum.2025.1509346.
Wang Q, Zhou J, Gong G Front Pharmacol. 2025; 16:1496774.
PMID: 39981187 PMC: 11839657. DOI: 10.3389/fphar.2025.1496774.